Real-world outcomes of patients with advanced-stage hepatocellular carcinoma receiving combination therapy with atezolizumab and bevacizumab: A South Australian statewide experience

被引：0
|
作者：
Chan, A. [1 ,2 ]
Saluja, H. [1 ]
Nind, G. [3 ]
Singhal, N. [1 ]
Roy, A. [4 ]
Mcgregor, M. [2 ]
Chinnaratha, A. [2 ]
机构：
[1] Royal Adelaide Hosp, Adelaide, SA, Australia
[2] Lyell McEwin Hosp, Adelaide, SA, Australia
[3] Queen Elizabeth Hosp, Adelaide, SA, Australia
[4] Flinders Med Ctr, Adelaide, SA, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
118
引用
收藏
页码：56 / 57
页数：2
相关论文
共 50 条
  • [21] Real-world data: Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in Veteran Health Administration
    Alkadimi, Munaf
    Lucero, Kana
    Boyle, Lauren Diaz
    Fierro, Maria Elena
    Franklin, Kathleen
    Nooruddin, Zohra
    Mader, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Brown, Timothy J.
    Mamtani, Ronac
    Gimotty, Phyllis A.
    Karasic, Thomas B.
    Yang, Yu-Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
  • [23] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Timothy J. Brown
    Ronac Mamtani
    Phyllis A. Gimotty
    Thomas B. Karasic
    Yu-Xiao Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
  • [24] Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications
    Lee, Cha Len
    Freeman, Mark
    Burak, Kelly W.
    Moffat, Gordon T.
    O'Donnell, Conor D. J.
    Ding, Philip Q.
    Lyubetska, Hanna
    Meyers, Brandon M.
    Gordon, Vallerie
    Kosyachkova, Ekaterina
    Bucur, Roxana
    Cheung, Winson Y.
    Knox, Jennifer J.
    Tam, Vincent C.
    CANCERS, 2024, 16 (16)
  • [25] ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): REAL-WORLD EXPERIENCE FROM A US COMMUNITY ONCOLOGY NETWORK
    Cosgrove, David
    Tan, Amie
    Hernandez, Sairy
    Mahrus, Sami
    Osterland, Andrew
    Murphy, John
    Loaiza-Bonilla, Arturo
    HEPATOLOGY, 2022, 76 : S1308 - S1309
  • [26] REAL-WORLD EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN THE PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTIINSTITUTIONAL COHORT IN TAIWAN
    Kuo, Y. C.
    Chang, K. C.
    Chen, H. Y.
    VALUE IN HEALTH, 2022, 25 (12) : S475 - S475
  • [27] Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)
    Singal, A. G.
    Ozgurdal, K.
    Fan, X.
    Vassilev, Z.
    Chen, C-C.
    Multani, J. K.
    Zhou, Z.
    He, J.
    Pisa, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S867 - S867
  • [28] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
    Rossari, F.
    Tada, T.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Persano, M.
    Piscaglia, F.
    Scartozzi, M.
    Cascinu, S.
    Rimini, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
  • [29] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
    Rossari, Federico
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Yoo, Changhoon
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Bergamo, Francesca
    Amadeo, Elisabeth
    Vitiello, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Iavarone, Massimo
    Cabibbo, Giuseppe
    Montes, Margarida
    Foschi, Francesco Giuseppe
    Vivaldi, Caterina
    Solda, Caterina
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Hiraoka, Atsushi
    LIVER CANCER, 2024, 13 (05) : 522 - 536
  • [30] A single-center, real-world experience of atezolizumab plus bevacizumab as first-line therapy in patients with unresectable hepatocellular carcinoma, including patients with advanced cirrhosis.
    Parekh, Jay
    Abraham, Soniya
    Andanamala, Haripriya
    Rehman, Asad
    Ahearn, Paul
    Adjepong, Yaw
    Buller, Gregory
    Stein, Stacey
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 445 - 445
12345